Determinants of the activity and substrate recognition of breast cancer resistance protein (ABCG2)

References

• Ahmed-Belkacem A, Macalou S, Borrelli F, et al. (2007). Nonprenylated rotenoids, a new class of potent breast cancer resistance protein inhibitors. J Med Chem 50:1933–1938
   PubMed Web of Science ®Google Scholar
• Ahmed-Belkacem A, Pozza A, Muñoz-Martínez F, et al. (2005). Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer Res 65:4852–4860
   PubMed Web of Science ®Google Scholar
• Allen JD, van Dort SC, Buitelaar M, et al. (2003). Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res 63:1339–1344
   PubMed Web of Science ®Google Scholar
• Allen JD, Brinkhuis RF, Wijnholds J, Schinkel AH. (1999). The mouse bcrp1/mxr/abcp gene: Amplifcation and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 59:4237–4241
   PubMed Web of Science ®Google Scholar
• Allen JD, Jackson SC, Schinkel AH. (2002a). A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for doxorubicin resistance. Cancer Res 62:2294–2299
   PubMed Web of Science ®Google Scholar
• Allen JD, Schinkel AH. (2002). Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther 1:427–434
   PubMed Web of Science ®Google Scholar
• Allen JD, van Loevezijn A, Lakhai JM, et al. (2002b). Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1:417–425
   PubMed Web of Science ®Google Scholar
• An G, Gallegos J, Morris ME. (2011). The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux. Drug Metab Dispos 39:426–432
   PubMed Web of Science ®Google Scholar
• Bäckström G, Taipalensuu J, Melhus H, et al. (2003). Genetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish population. Eur J Pharm Sci 18:359–364
   PubMed Web of Science ®Google Scholar
• Beéry E, Rajnai Z, Abonyi T, et al. (2012). ABCG2 modulates chlorothiazide permeability in vitro characterization of its interaction. Drug Metab Pharmacokinet 27:349–353
   PubMed Web of Science ®Google Scholar
• Bihorel S, Camenisch G, Lemaire M, Scherrmann J-M. (2007). Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm Res 24:1720–1728
   PubMed Web of Science ®Google Scholar
• Boumendjel A, Macalou S, Ahmed-Belkacem A, et al. (2007). Acridone derivatives: Design, synthesis, and inhibition of breast cancer resistance protein ABCG2. Bioorg Med Chem 15:2892–2897
   PubMed Web of Science ®Google Scholar
• Breedveld P, Zelcer N, Pluim D, et al. (2004). Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: Potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 64:5804–5811
   PubMed Web of Science ®Google Scholar
• Brooks T, Minderman H, O’Loughlin KL, et al. (2003). Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther 2:1195–1205
   PubMed Web of Science ®Google Scholar
• Brooks TA, Kennedy DR, Gruol DJ, et al. (2004). Structure-activity analysis of taxane-based broad-spectrum multidrug resistance modulators. Anticancer Res 24:409–416
   PubMed Web of Science ®Google Scholar
• Cai X, Bikadi Z, Ni Z, et al. (2010). Role of basic residues within or near the predicted transmembrane helix 2 of the human breast cancer resistance protein in drug transport. J Pharmacol Exp Ther 333:670–681
   Google Scholar
• Chen Y-N, Mickleys LA, Schwartz AM, et al. (1990). Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem 265:10073–10080
   PubMed Web of Science ®Google Scholar
• Chen Z-S, Robey RW, Belinsky MG, et al. (2003). Transport of methotrexate, methotrexate polyglutamates, and 17β-estradiol 17-(β-d-glucuronide) by ABCG2: Effects of acquired mutations at R482 on methotrexate transport. Cancer Res 63:4048–4054
   PubMed Web of Science ®Google Scholar
• Clark R, Kerr ID, Callaghan R. (2006). Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter. Br J Pharmacol 149:506–515
   PubMed Web of Science ®Google Scholar
• Conseil G, Deeley RG, Cole SPC. (2006). Functional importance of three basic residues clustered at the cytosolic interface of transmembrane helix 15 in the multidrug and organic anion transporter MRP1 (ABCC1). J Biol Chem 281:43–50
   PubMed Web of Science ®Google Scholar
• Cooray HC, Janvilisri T, van Veen HW, et al. (2004). Interaction of the breast cancer resistance protein with plant polyphenols. Biochem Biophys Res Commun 317:269–275
   PubMed Web of Science ®Google Scholar
• Cowan KH, Goldsmith ME, Levine RM, et al. (1982). Dihydrofolate reductase gene amplification and possible rearrangement in estrogen-responsive methotrexate-resistant human breast cancer cells. J Biol Chem 257:15079–15086
   PubMedGoogle Scholar
• Cygalova LH, Hofman J, Ceckova M, Staud F. (2009). Transplacental pharmacokinetics of glyburide, rhodamine 123, and BODIPY FL Prazosin: Effect of drug efflux transporters and lipid solubility. J Pharmacol Exp Ther 331:1118–1125
   PubMed Web of Science ®Google Scholar
• Dai C, Tiwari AK, Wu C-P, et al. (2008). Lapatinib (tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 68:7905–7914
   PubMed Web of Science ®Google Scholar
• Davidson AL, Sharma S. (1997). Mutation of a single MalK subunit severely impairs maltose transport activity in Escherichia coli. J Bacteriol 179:5458–5464
   PubMed Web of Science ®Google Scholar
• de Bruin M, Miyake K, Litman T, et al. (1999). Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett, 146:117–126
   PubMed Web of Science ®Google Scholar
• de Jong FA, Marsh S, Mathijssen RHJ, et al. (2004). ABCG2 pharmacogenetics: Ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res 10:5889–5894
   PubMed Web of Science ®Google Scholar
• de Wolf C, Jansen R, Yamaguchi H, et al. (2008). Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther 7:3092–3102
   PubMed Web of Science ®Google Scholar
• Dohse M, Scharenberg C, Shukla S, et al. (2010). Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metabol Dispos 38:1371–1380
   PubMed Web of Science ®Google Scholar
• Doyle LA, Ross DD. (2003). Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340–7358
   PubMed Web of Science ®Google Scholar
• Doyle LA, Yang W, Abruzzo LV, et al. (1998). A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665–15670
   PubMed Web of Science ®Google Scholar
• Doyle LA, Yang W, Gao Y, et al. (1996). Novobiocin increases the accumulation of daunorubicin in an atypical multidrug-resistant breast cancer subline. Proc Am Soc Clin Oncol 15:398
   Google Scholar
• Ebert B, Seidel A, Lampen A. (2005). Identification of BCRP as transporter of benzo [a] pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Access 26:1754–1763
   Google Scholar
• Ebert B, Seidel A, Lampen A. (2007). Phytochemicals induce breast cancer resistance protein in Caco-2 cells and enhance the transport of benzo[a]pyrene-3-sulfate. Toxicol Sci 96:227–236
   PubMed Web of Science ®Google Scholar
• Ejendal KFK, Diop NK, Schweiger LC, Hrycyna CA. (2006). The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding. Protein Sci 15:1597–1607
   PubMed Web of Science ®Google Scholar
• Enokizono J, Kusuhara H, Ose A, et al. (2008). Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. Drug Metabol Dispos 36:995–1002
   PubMed Web of Science ®Google Scholar
• Enokizono J, Kusuhara H, Sugiyama Y. (2007). Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens. Mol. Pharmacol 72:967–975
   PubMed Web of Science ®Google Scholar
• Fairchild CR, Ivy SP, Whang-Peng J, et al. (1987). Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res 47:5141–5148
   PubMed Web of Science ®Google Scholar
• FDA. (2009). Guidance for industry. Assay Development for Immunogenicity Testing of Therapeutic Proteins. FDA, 1–55
   Google Scholar
• FDA. (2012). Guidance for industry. Drug interaction studies — Study design, data analysis, implications for dosing, and labeling recommendations. FDA, 1–35
   Google Scholar
• Gandhi YA, Morris ME. (2009). Structure–activity relationships and quantitative structure–activity relationships for breast cancer resistance protein (ABCG2). AAPS J 11:541–552
   PubMed Web of Science ®Google Scholar
• Giri N, Shaik N, Pan G, et al. (2008). Investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) on pharmacokinetics and central nervous system penetration of abacavir and zidovudine in the mouse. Drug Metabol Dispos 36:1476–1484
   PubMed Web of Science ®Google Scholar
• Gupta A, Zhang Y, Unadkat JD, Mao Q. (2004). HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther 310:334–341
   PubMed Web of Science ®Google Scholar
• Han Y, Riwanto M, Go M-L, Ee PLR. (2008). Modulation of breast cancer resistance protein (BCRP/ABCG2) by non-basic chalcone analogues. Eur J Pharm Sci 35:30–41
   PubMed Web of Science ®Google Scholar
• Hecht SS. (2000). Inhibition of carcinogenesis by isothiocyanates. Drug Metabol Rev 32:395–411
   PubMed Web of Science ®Google Scholar
• Henriksen U, Fog JU, Litman T, Gether U. (2005a). Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2. J Biol Chem 280:36926–36934
   PubMed Web of Science ®Google Scholar
• Henriksen U, Gether U, Litman T. (2005b). Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2. J Cell Sci 118:1417–1426
   PubMed Web of Science ®Google Scholar
• Higgins CF. (2007). Multiple molecular mechanisms for multidrug resistance transporters. Nature 446:749–757
   PubMed Web of Science ®Google Scholar
• Hirano M, Maeda K, Matsushima S, et al. (2005). Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 68:800–807
   PubMed Web of Science ®Google Scholar
• Honjo Y, Hrycyna CA, Yan Q-W, et al. (2001). Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61:6635–6639
   PubMed Web of Science ®Google Scholar
• Honjo Y, Morisaki K, Huff LM, et al. (2002). Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1). Cancer Biol Ther 1:696–702
   PubMed Web of Science ®Google Scholar
• Hou Y, Li C-Z, Palaniyandi K, et al. (2009). Effects of putative catalytic base mutation E211Q on ABCG2-mediated methotrexate transport. Biochemistry 48:9122–9131
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Germain GS, Harwood FC, et al. (2004). Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 64:2333–2337
   PubMed Web of Science ®Google Scholar
• Huang L, Wang Y, Grimm S. (2006). ATP-dependent transport of rosuvastatin in membrane vesicles expressing cancer resistance protein. Drug Metabol Dispos 34:738–742
   PubMed Web of Science ®Google Scholar
• Ifergan I, Shafran A, Jansen G, et al. (2004). Folate deprivation results in the loss of breast cancer resistance protein (BCRP/ABCG2) expression. A role for BCRP in cellular folate homeostasis. J Biol Chem 279:25527–25534
   PubMed Web of Science ®Google Scholar
• Iida A, Saito S, Sekine A, et al. (2002). Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8. J Hum Genet 47:285–310
   PubMed Web of Science ®Google Scholar
• Imai Y, Asada S, Tsukahara S, et al. (2003). Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol 64:610–618
   PubMed Web of Science ®Google Scholar
• Imai Y, Tsukahara S, Asada S, Sugimoto Y. (2004). Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res 64:4346–52
   PubMed Web of Science ®Google Scholar
• Imai Y, Tsukahara S, Ishikawa E, et al. (2002). Estrone and 17β-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. Jpn J Cancer Res 93:231–235
   PubMedGoogle Scholar
• Ishikawa T, Kasamatsu S, Hagiwara Y, et al. (2003). Expression and functional characterization of human ABC transporter ABCG2 variants in insect cells. Drug Metab Pharmacokinet 18:194–202
   PubMedGoogle Scholar
• Itoda M, Aito YS, Hirao KS, et al. (2003). Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotacan. Drug Metabol Pharmacokinet 18:212–217
   PubMedGoogle Scholar
• Janvilisri T, Shahi S, Venter H, et al. (2005). Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J 385:419–426
   PubMed Web of Science ®Google Scholar
• Janvilisri T, Venter H, Shahi S, et al. (2003). Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem 278:20645–20651
   PubMed Web of Science ®Google Scholar
• Ji Y, Morris ME. (2005). Membrane transport of dietary phenethyl isothiocyanate by ABCG2 (breast cancer resistance protein). Mol Pharm 2:414–419
   PubMed Web of Science ®Google Scholar
• Jin J, Shahi S, Kang HK, et al. (2006). Metabolites of ginsenosides as novel BCRP inhibitors. Biochem Biophys Res Commun 345:1308–1314
   PubMed Web of Science ®Google Scholar
• Jonker JW, Buitelaar M, Wagenaar E, et al. (2002). The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci USA 99:15649–15654
   PubMed Web of Science ®Google Scholar
• Jonker JW, Merino G, Musters S, et al. (2005). The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 11:127–129
   PubMed Web of Science ®Google Scholar
• Kage K, Fujita T, Sugimoto Y. (2005). Role of Cys-603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2. Cancer Sci 96:866–872
   PubMed Web of Science ®Google Scholar
• Kalgutkar AS, Feng B, Nguyen HT, et al. (2007). Role of transporters in the dispostion of the selective phosphodiesterase-4 inhibitor (+)-2-[4({[2-benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl-3-fluoro-phenoxy]-propionic acid in rat and human. Drug Metabol Dispos 35:2111–2118
   PubMed Web of Science ®Google Scholar
• Kawabata S, Oka M, Shiozawa K, et al. (2001). Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 280:1216–1223
   PubMed Web of Science ®Google Scholar
• Kim H-S, Sunwoo YE, Ryu JY, et al. (2007). The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine. Br J Clin Pharmacol 64:645–654
   PubMed Web of Science ®Google Scholar
• Kitamura S, Maeda K, Wang Y, Sugiyama Y. (2008). Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metabol Dispos 36:2014–2023
   PubMed Web of Science ®Google Scholar
• Kobayashi D, Ieiri I, Hirota T, et al. (2005). Functional assesment of ABCG2 (BCRP) gene polymorphism to protein expression in human placenta. Drug Metabol Dispos 33:94–101
   PubMed Web of Science ®Google Scholar
• Komatani H, Kotani H, Hara Y, et al. (2001). Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. Cancer Res 61:2827–2832
   PubMed Web of Science ®Google Scholar
• Krishnamurthy P, Ross DD, Nakanishi T, et al. (2004). The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 279:24218–24225
   PubMed Web of Science ®Google Scholar
• Krishnamurthy P, Schuetz JD. (2005). The ABC transporter Abcg2/Bcrp: Role in hypoxia mediated survival. BioMetals 18:349–358
   PubMed Web of Science ®Google Scholar
• Lapinski PE, Neubig RR, Raghavan M. (2001). Walker A lysine mutations of TAP1 and TAP2 interfere with peptide translocation but not peptide binding. J Biol Chem 276:7526–7533
   PubMed Web of Science ®Google Scholar
• Li J, Cusatis G, Brahmer J, et al. (2007). Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol Ther 6:432–438
   PubMed Web of Science ®Google Scholar
• Lin X, Skolnik S, Chen X, Wang J. (2011). Attenuation of intestinal absorption by major efflux transporters: Quantitative tools and strategies using a Caco-2 model. Drug Metabol Dispos 39:265–274
   PubMed Web of Science ®Google Scholar
• Litman T, Brangi M, Hudson E, et al. (2000). The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113:2011–2021
   PubMed Web of Science ®Google Scholar
• Liu X-L, Tee H-W, Go M-L. (2008a). Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein. Bioorg Med Chem 16:171–180
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang Y, Qi J, et al. (2008b). Effect of cysteine mutagenesis on the function and disulfide bond formation of human ABCG2. J Pharmacol Exp Ther 326:33–40
   PubMed Web of Science ®Google Scholar
• Ma J, Maliepaard M, Nooter K, et al. (1998). Reduced cellular accumulation of topotecan: A novel mechanism of resistance in a human ovarian cancer cell line. Br J Cancer 77:1645–1652
   PubMed Web of Science ®Google Scholar
• Maliepaard M, van Gastelen MA, Tohgo A, et al. (2001). Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res 7:935–941
   PubMed Web of Science ®Google Scholar
• Marquez B, van Bambeke F. (2011). ABC multidrug transporters: Target for modulation of drug pharmacokinetics and drug-drug interactions. Curr Drug Targets 12:600–620
   PubMed Web of Science ®Google Scholar
• Matsson P, Englund G, Ahlin G, et al. (2007). A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2). J Pharmacol Exp Ther 323:19–30
   PubMed Web of Science ®Google Scholar
• Matsson P, Pedersen JM, Norinder U, et al. (2009). Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 26:1816–1831
   PubMed Web of Science ®Google Scholar
• McDevitt CA, Collins R, Kerr ID, Callaghan R. (2009). Purification and structural analyses of ABCG2. Adv Drug Deliv Rev 61:57–65
   PubMed Web of Science ®Google Scholar
• McDevitt CA, Crowley E, Hobbs G, et al. (2008). Is ATP binding responsible for initiating drug translocation by the multidrug transporter ABCG2? FEBS J 275:4354–4362
   PubMed Web of Science ®Google Scholar
• Merino G, Álvarez AI, Pulido MM, et al. (2006). Breast cancer resistance protein (BCRP/ABCG2) transports fluoroquinolone antibiotics and affects their oral availability, pharmacokinetics, and milk secretion. Drug Metabol Dispos 34:690–695
   PubMed Web of Science ®Google Scholar
• Mitomo H, Kato R, Ito A, et al. (2003). A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: Critical role of arginine-482 in methotrexate transport. Biochem J 373:767–774
   PubMed Web of Science ®Google Scholar
• Miwa M, Tsukahara S, Ishikawa E, et al. (2003). Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants. Int J Cancer 107:757–763
   PubMed Web of Science ®Google Scholar
• Mizuarai S, Aozasa N, Kotani H. (2004). Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer 109:238–246
   PubMed Web of Science ®Google Scholar
• Mohrmann K, van Eijndhoven MAJ, Schinkel AH, Schellens JHM. (2005). Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2). Cancer Chemother Pharmacol 56:344–350
   Google Scholar
• Muenster U, Grieshop B, Ickenroth K, Gnoth MJ. (2008). Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions. Pharm Res 25:2320–2326
   PubMed Web of Science ®Google Scholar
• Müller M, Bakos É, Welker E, et al. (1996). Altered drug-stimulated ATPase activity in mutants of the human multidrug resistance protein. J Biol Chem 271:1877–1883
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Saito H, Ikegami Y, et al. (2006). Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer. Cancer Lett 234:81–89
   PubMed Web of Science ®Google Scholar
• Ni Z, Bikadi Z, Rosenberg MF, Mao Q. (2010a). Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metabol 11:603–617
   PubMed Web of Science ®Google Scholar
• Ni Z, Bikadi Z, Shuster DL, et al. (2011). Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity. Biochemistry 50:8057–8066
   PubMed Web of Science ®Google Scholar
• Ni Z, Mark ME, Cai X, Mao Q. (2010b). Fluorescence resonance energy transfer (FRET) analysis demonstrates dimer/oligomer formation of the human breast cancer resistance protein (BCRP/ABCG2) in intact cells. Int J Biochem Mol Biol 1:1–11
   PubMedGoogle Scholar
• Özvegy C, Litman T, Szakács G, et al. (2001). Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun 285:111–117
   PubMed Web of Science ®Google Scholar
• Özvegy C, Váradi A, Sarkadi B. (2002). Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. J Biol Chem 277:47980–47990
   PubMed Web of Science ®Google Scholar
• Özvegy-Laczka C, Hegedüs T, Várady G, et al. (2004). High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 65:1485–1495
   PubMed Web of Science ®Google Scholar
• Özvegy-Laczka C, Köblös G, Sarkadi B, Váradi A. (2005). Single amino acid (482) variants of the ABCG2 multidrug transporter: Major differences in transport capacity and substrate recognition. Biochim Biophys Acta 1668:53–63
   PubMed Web of Science ®Google Scholar
• Pal A, Mehn D, Molnar E, et al. (2007). Cholesterol potentiates ABCG2 activity in a heterologous expression system: Improved in vitro model to study function of human ABCG2. J Pharmacol Exp Ther 321:1085–1094
   PubMed Web of Science ®Google Scholar
• Pan G, Giri N, Elmquist WF. (2007). Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine. Drug Metab Dispos 35:1165–1173
   PubMed Web of Science ®Google Scholar
• Pavek P, Merino G, Wagenaar E, et al. (2005). Human breast cancer resistance protein: Interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther 312:144–152
   PubMed Web of Science ®Google Scholar
• Pick A, Müller H, Pajeva IK, et al. (2011). Structure–activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). Bioorg Med Chem Elsevier Ltd 19:2090–2102
   PubMed Web of Science ®Google Scholar
• Polgar O, Robey RW, Morisaki K, et al. (2004). Mutational analysis of ABCG2: Role of the GXXXG motif. Biochemistry 43:9448–9456
   PubMed Web of Science ®Google Scholar
• Pozza A, Perez-Victoria JM, Sardo A, et al. (2006). Purification of breast cancer resistance protein ABCG2 and role of arginine-482. Cell Mol Life Sci 63:1912–1922
   PubMed Web of Science ®Google Scholar
• Rabindran SK, He H, Singh M, et al. (1998). Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res 58:5850–5858
   PubMed Web of Science ®Google Scholar
• Rabindran SK, Ross DD, Doyle LA, et al. (2000). Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 60:47–50
   PubMed Web of Science ®Google Scholar
• Rajendra R, Gounder MK, Saleem A, et al. (2003). Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. Cancer Res 63:3228–3233
   PubMed Web of Science ®Google Scholar
• Robey RW, Honjo Y, Morisaki K, et al. (2003). Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 89:1971–1978
   PubMed Web of Science ®Google Scholar
• Robey RW, Honjo Y, van de Laar A, et al. (2001a). A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim Biophys Acta 1512:171–182
   PubMed Web of Science ®Google Scholar
• Robey RW, Medina-Pérez WY, Nishiyama K, et al. (2001b). Overexpression of the ATP-binding cassette half-transporter, ABCG2 (MXR/BCRP/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 2:145–152
   Google Scholar
• Robey RW, Steadman K, Polgar O, Bates SE. (2005). ABCG2-mediated transport of photosensitizers. Cancer Biol Ther 4:187–194
   PubMed Web of Science ®Google Scholar
• Robey RW, Steadman K, Polgar O, et al. (2004). Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res 64:1242–1246
   PubMed Web of Science ®Google Scholar
• Robey RW, To KKK, Polgar O, et al. (2009). ABCG2: A perspective. Adv Drug Deliv Rev 61:3–13
   PubMed Web of Science ®Google Scholar
• Rosenbach-Belkin V, Chen L, Fiedor L, et al. (1996). Serine conjugates of chlorophyll and bacteriochlorophyll: Photocytotoxicity in vitro and tissue distribution in mice bearing melanoma tumors. Photochem Photobiol 64:174–181
   PubMed Web of Science ®Google Scholar
• Rosenberg MF, Bikadi Z, Chan J, et al. (2010). The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone. Structure 18:482–493
   PubMed Web of Science ®Google Scholar
• Ross DD, Yang W, Abruzzo LV, et al. (1999). Atypical multidrug resistance: Breast cancer resistance protein messenger RNA in mitoxantrone-selected cell lines. J Natl Cancer Inst 91:429–433
   PubMed Web of Science ®Google Scholar
• Russ WP, Engelman DM. (2000). The GxxxG motif: A framework for transmembrane helix-helix association. J Mol Biol 296:911–919
   PubMed Web of Science ®Google Scholar
• Ryu S, Kawabe T, Nada S, Yamaguchi A. (2000). Identification of basic residues involved in drug export function of human multidrug resistance-associated protein 2. J Biol Chem 275:39617–39624
   PubMed Web of Science ®Google Scholar
• Saito H, Hirano H, Nakagawa H, et al. (2006). A new strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions. J Pharmacol Exp Ther 317:1114–1124
   PubMed Web of Science ®Google Scholar
• Scharenberg CW, Harkey MA, Torok-Storb B. (2002). The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99:507–512
   PubMed Web of Science ®Google Scholar
• Schneider E, Horton JK, Yang C-H, et al. (1994). Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 54:152–158
   PubMed Web of Science ®Google Scholar
• Shigeta J, Katayama K, Mitsuhashi J, et al. (2010). BCRP/ABCG2 confers anticancer drug resistance without covalent dimerization. Cancer Sci 101:1813–1821
   PubMed Web of Science ®Google Scholar
• Shiozawa K, Oka M, Soda H, et al. (2004). Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Int J Cancer 108:146–151
   PubMed Web of Science ®Google Scholar
• Shukla S, Robey RW, Bates SE, Ambudkar SV. (2006). The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. Biochemistry 45:8940–8951
   PubMed Web of Science ®Google Scholar
• Shukla S, Wu C-P, Nandigama K, Ambudkar SV. (2007). The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2. Mol Cancer Ther 6:3279–3286
   PubMed Web of Science ®Google Scholar
• Shukla S, Zaher H, Hartz A, et al. (2009). Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res 26:480–487
   PubMed Web of Science ®Google Scholar
• Staud F, Pavek P. (2005). Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol 37:720–725
   PubMed Web of Science ®Google Scholar
• Subczynski WK, Wisniewska A. (2000). Physical properties of lipid bilayer membranes: Relevance to biological functions. Acta Biochim Pol 47:613–622
   PubMed Web of Science ®Google Scholar
• Sugimoto Y, Tsukahara S, Imai Y, et al. (2003). Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol Cancer Ther 2:105–112
   PubMed Web of Science ®Google Scholar
• Szabó K, Welker E, Bakos É, et al. (1998). Drug-stimulated nucleotide trapping in the human multidrug transporter MDR1. J Biol Chem 273:10132–10138
   PubMed Web of Science ®Google Scholar
• Szczygieł M, Urbańska K, Jurecka P, et al. (2008). Central metal determines pharmacokinetics of chlorophyll-derived xenobiotics. J Med Chem 51:4412–4418
   PubMed Web of Science ®Google Scholar
• Taguchi Y, Kino K, Morishima M, et al. (1997). Alteration of substrate specificity by mutations at the His61 position in predicted transmembrane domain 1 of human MDR1/P-glycoprotein. Biochemistry 36:8883–8889
   PubMed Web of Science ®Google Scholar
• Tamura A, Watanabe M, Saito H, et al. (2006). Functional validation of the genetic polymorphisms of human ATP-binding cassette (ABC) transporter ABCG2: Identification of alleles that are defective in porphyrin transport. Mol Pharmacol 70:287–296
   PubMed Web of Science ®Google Scholar
• Telbisz A, Müller M, Özvegy-Laczka C, et al. (2007). Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter. Biochim Biophys Acta 1768:2698–2713
   PubMed Web of Science ®Google Scholar
• Valdameri G, Genoux-Bastide E, Peres B, et al. (2012a). Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein. J Med Chem 55:966–970
   PubMed Web of Science ®Google Scholar
• Valdameri G, Pereira Rangel L, Spatafora C, et al. (2012b). Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein. ACS Chem Biol 7:322–330
   PubMedGoogle Scholar
• van de Wetering K, Burkon A, Feddema W, et al. (2009). Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol. Mol Pharmacol 75:876–885
   PubMed Web of Science ®Google Scholar
• van der Heijden J, de Jong MC, Dijkmans BAC, et al. (2004). Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFα. Ann Rheum Dis 63:138–144
   PubMed Web of Science ®Google Scholar
• van Hattum AH, Hoogsteen IJ, Schlüper HMM, et al. (2002). Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity. Br J Cancer 87:665–672
   PubMed Web of Science ®Google Scholar
• van Herwaarden AE, Wagenaar E, Karnekamp B, et al. (2006). Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis 27:123–130
   PubMed Web of Science ®Google Scholar
• van Herwaarden AE, Wagenaar E, Merino G, et al. (2007). Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol Cell Biol 27:1247–1253
   PubMed Web of Science ®Google Scholar
• van Veen HW, Margolles A, Müller M, et al. (2000). The homodimeric ATP-binding cassette transporter LmrA mediates multidrug transport by an alternating two-site (two-cylinder engine) mechanism. EMBO J 19:2503–2514
   PubMed Web of Science ®Google Scholar
• Velamakanni S, Wei SL, Janvilisri T, van Veen HW. (2007). ABCG transporters: Structure, substrate specificities and physiological roles. J Bioenerg Biomembr 39:465–471
   PubMed Web of Science ®Google Scholar
• Vethanayagam R, Wang H, Gupta A, et al. (2005). Functional analysis of the human variants of breast cancer resistance protein: I206L, N590Y, and D620N. Drug Metab Dispos 33:697–705
   PubMed Web of Science ®Google Scholar
• Volk EL, Schneider E. (2003). Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 63:5538–5543
   PubMed Web of Science ®Google Scholar
• Wang H, Lee E-W, Cai X, et al. (2009). Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence. Biochemistry 47:13778–13787
   Web of Science ®Google Scholar
• Wang J-S, Zhu H-J, Markowitz JS, et al. (2008). Antipsychotic drugs inhibit the function of breast cancer resistance protein. Basic Clin Pharmacol Toxicol 103:336–341
   PubMed Web of Science ®Google Scholar
• Wang L, McNamara PJ. (2012). Stereoselective interaction of pantoprazole with ABCG2. I. Drug accumulation in rat milk. Drug Metab Dispos 40:1018–1023
   PubMed Web of Science ®Google Scholar
• Wierdl M, Wall A, Morton CL, et al. (2003). Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance. Mol Pharmacol 64:279–288
   PubMed Web of Science ®Google Scholar
• Wiese M, Pajeva IK. (2001). Structure-activity relationships of multidrug resistance reversers. Curr Med Chem 8:685–713
   PubMed Web of Science ®Google Scholar
• Woodward OM, Köttgen A, Coresh J, et al. (2009). Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci USA 106:10338–10342
   PubMed Web of Science ®Google Scholar
• Xia CQ, Liu N, Miwa GT, Gan L-S. (2007). Interactions of cyclosporin A with breast cancer resistance protein. Drug Metab Dispos 35:576–582
   PubMed Web of Science ®Google Scholar
• Xu J, Peng H, Chen Q, et al. (2007). Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity. Cancer Res 67:4373–4381
   PubMed Web of Science ®Google Scholar
• Yanase K, Tsukahara S, Asada S, et al. (2004). Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther 3:1119–1125
   PubMed Web of Science ®Google Scholar
• Yoshikawa M, Ikegami Y, Hayasaka S, et al. (2004). Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. Int J Cancer 110:921–927
   PubMed Web of Science ®Google Scholar
• Zaher H, Khan AA, Palandra J, et al. (2006). Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol Pharm 3:55–61
   PubMed Web of Science ®Google Scholar
• Zhang S, Yang X, Morris ME. (2004a). Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm Res 21:1263–1273
   PubMed Web of Science ®Google Scholar
• Zhang S, Yang X, Morris ME. (2004b). Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 65:1208–1216
   PubMed Web of Science ®Google Scholar
• Zhang Y, Gupta A, Wang H, et al. (2005). BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm Res 22:2023–2034
   PubMed Web of Science ®Google Scholar
• Zheng X, Morgan J, Pandey SK, et al. (2009). Conjugation of 2′-(1′-hexyloxyethyl)-2-devinylpyropheophorbide-a (HPPH) to carbohydrates changes its subcellular distribution and enhances photodynamic activity in vivo. J Med Chem 52:4306–4318
   Google Scholar
• Zhou L, Naraharisetti SB, Wang H, et al. (2008). The breast cancer resistance protein (Bcrp1/Abcg2) limits fetal distribution of glyburide in the pregnant mouse: An Obstetric-Fetal Pharmacology Research Unit Network and University of Washington Specialized Center of Research Study. Mol Pharmacol 73:949–959
   PubMed Web of Science ®Google Scholar
• Zhou S, Zong Y, Ney PA, et al. (2005). Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels. Blood 105:2571–2576
   PubMed Web of Science ®Google Scholar